All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The International Myeloma Working Group (IMWG) has developed a new Revised-International Staging System (R-ISS), which builds on the ISS by taking into account several additional factors (serum lactate dehydrogenase levels (LDH) and high-risk chromosomal abnormalities (CA)) in order to stratify multiple myeloma (MM) patients into three groups with varying outcomes.
Verónica González-Calle, from the Division of Hematology and Oncology Mayo Clinic, Scottsdale, USA, and colleagues, conducted a study to determine whether this new R-ISS risk model could be used to predict clinical outcomes (i.e. survival rate) in a cohort of newly diagnosed (ND) transplant-eligible MM patients. Their findings were published in the Annals of Hematology in April 2018.
Table 1. Characteristics of transplant-eligible MM patients who underwent ASCT between 2004–2014
The reclassification of MM patients who underwent ASCT at diagnosis showed that R-ISS was an independent and reliable predictor for OS after ASCT. There was a significantly shorter OS in patients classified as R-ISS IIb in comparison to patients classified as R-ISS IIa. It was concluded that the R-ISS can improve the risk-stratification of transplant-eligible MM patients in terms of predicting OS rates. In turn, this information can help to guide more effective treatment decisions.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox